MCID: SRT004
MIFTS: 50

Serotonin Syndrome

Categories: Neuronal diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Serotonin Syndrome

MalaCards integrated aliases for Serotonin Syndrome:

Name: Serotonin Syndrome 59 55
Malignant Carcinoid Syndrome 73
Serotonergic Syndrome 59
Serotonin Toxidrome 59
Serotonin Toxicity 59
Serotonin Storm 59

Characteristics:

Orphanet epidemiological data:

59
serotonin syndrome
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA43116
MESH via Orphanet 45 D020230
UMLS via Orphanet 74 C0699828
UMLS 73 C0024586

Summaries for Serotonin Syndrome

MalaCards based summary : Serotonin Syndrome, also known as malignant carcinoid syndrome, is related to fibromyalgia and depression. An important gene associated with Serotonin Syndrome is HTR3A (5-Hydroxytryptamine Receptor 3A), and among its related pathways/superpathways are Peptide ligand-binding receptors and Serotonergic synapse. The drugs Sertraline and Clomipramine have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Serotonin syndrome (SS) is a group of symptoms that may occur following use of certain serotonergic... more...

Related Diseases for Serotonin Syndrome

Diseases related to Serotonin Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)
# Related Disease Score Top Affiliating Genes
1 fibromyalgia 30.5 HTR2A HTR3A SLC6A4
2 depression 30.3 HTR1A HTR2A HTR3A MAOA SLC6A4
3 post-traumatic stress disorder 29.9 HTR2A MAOA MAOB SLC6A4
4 obsessive-compulsive disorder 28.8 CYP2D6 HTR1A HTR2A HTR3A MAOA OXT
5 parkinson disease, late-onset 28.6 CYP2D6 HTR1A HTR2A MAOA MAOB SLC6A4
6 anxiety 28.4 CYP2D6 CYP3A4 HTR1A HTR2A HTR3A MAOA
7 schizoid personality disorder 10.9 HTR1A HTR2A
8 schizophrenia 5 10.9 HTR2A HTR3A
9 alzheimer disease 5 10.9 HTR2A SLC6A4
10 hypoactive sexual desire disorder 10.8 HTR1A HTR2A
11 substance-induced psychosis 10.8 HTR1A HTR2A
12 phobic disorder 10.7 HTR1A MAOA SLC6A4
13 premature ejaculation 10.7 HTR1A HTR3A SLC6A4
14 atypical depressive disorder 10.7 MAOA MAOB SLC6A4
15 psychosexual disorder 10.7 HTR1A HTR2A SLC6A4
16 dependent personality disorder 10.7 CYP3A4 MAOA MAOB
17 dysthymic disorder 10.7 HTR2A MAOA SLC6A4
18 agoraphobia 10.7 HTR1A MAOA SLC6A4
19 periodic limb movement disorder 10.7 HTR1A HTR2A SLC6A4
20 rumination disorder 10.7 HTR1A HTR3A
21 postpartum depression 10.7 HTR1A MAOA SLC6A4
22 adenoma of the pancreas 10.7 CHGA SST
23 paranoid schizophrenia 10.7 HTR2A MAOA SLC6A4
24 antisocial personality disorder 10.7 MAOA MAOB SLC6A4
25 paraphilia disorder 10.6 MAOA MAOB OXT
26 bipolar i disorder 10.6 HTR1A HTR2A SLC6A4
27 chronic fatigue syndrome 10.6 HTR1A MAOA SLC6A4
28 substance abuse 10.6 CYP2D6 MAOA SLC6A4
29 endogenous depression 10.6 MAOA OXT SLC6A4
30 gastrointestinal neuroendocrine tumor 10.6 CHGA SST
31 substance dependence 10.6 CYP2D6 MAOA SLC6A4
32 social phobia 10.6 HTR1A HTR3A MAOA SLC6A4
33 hemangioma of liver 10.5 CYP3A4 IFNA2
34 early-onset schizophrenia 10.5 HTR2A HTR3A MAOA SLC6A4
35 borderline personality disorder 10.5 HTR1A HTR2A MAOA SLC6A4
36 pancreatic gastrinoma 10.5 MEN1 SST
37 pathological gambling 10.5 HTR2A MAOA MAOB SLC6A4
38 kleptomania 10.5 CYP3A4 HTR1A MAOA SLC6A4
39 autoimmune atrophic gastritis 10.5 CHGA GAST
40 postgastrectomy syndrome 10.4 PYY SST
41 dyspepsia 10.4 HTR1A HTR3A SLC6A4 SST
42 pancreatic somatostatinoma 10.4 MEN1 SST
43 motion sickness 10.4 HTR1A HTR3A TAC1
44 glucagonoma 10.4 CHGA GHRH SST
45 pylorospasm 10.4 GAST SST
46 gastroparesis 10.3 CYP2D6 GAST HTR3A
47 generalized anxiety disorder 10.3 HTR1A HTR2A HTR3A MAOA SLC6A4
48 brunner syndrome 10.3 HTR1A HTR3A MAOA MAOB SLC6A4
49 personality disorder 10.3 HTR1A HTR2A MAOA MAOB SLC6A4
50 pituitary carcinoma 10.2 CHGA SST

Comorbidity relations with Serotonin Syndrome via Phenotypic Disease Network (PDN):


Intestinal Obstruction

Graphical network of the top 20 diseases related to Serotonin Syndrome:



Diseases related to Serotonin Syndrome

Symptoms & Phenotypes for Serotonin Syndrome

GenomeRNAi Phenotypes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
2 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A SLC6A4

MGI Mouse Phenotypes related to Serotonin Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10 HTR1A HTR2A HTR3A MAOA MAOB OXT
2 endocrine/exocrine gland MP:0005379 9.81 HTR3A MEN1 NOTCH1 OXT SLC6A4 CHGA
3 homeostasis/metabolism MP:0005376 9.8 SST SSTR1 CHGA GAST GHRH HTR1A
4 nervous system MP:0003631 9.4 GHRH HTR1A HTR3A MAOA MAOB MEN1

Drugs & Therapeutics for Serotonin Syndrome

Drugs for Serotonin Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 143)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sertraline Approved Phase 4,Not Applicable 79617-96-2 68617
2
Clomipramine Approved, Investigational, Vet_approved Phase 4 303-49-1 2801
3
Citalopram Approved Phase 4 59729-33-8 2771
4
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
5 Quetiapine Fumarate Phase 4 111974-72-2
6 Central Nervous System Depressants Phase 4
7 Serotonin Agents Phase 4,Phase 2,Not Applicable
8 Serotonin Uptake Inhibitors Phase 4,Not Applicable
9 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
10 Neurotransmitter Uptake Inhibitors Phase 4,Not Applicable
11 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
12 Cytochrome P-450 Enzyme Inhibitors Phase 4
13 Tranquilizing Agents Phase 4
14 Antidepressive Agents Phase 4,Not Applicable
15 Antidepressive Agents, Second-Generation Phase 4
16 Antidepressive Agents, Tricyclic Phase 4
17 Antipsychotic Agents Phase 4
18 Psychotropic Drugs Phase 4,Not Applicable
19
Serotonin Investigational, Nutraceutical Phase 4,Phase 2,Not Applicable 50-67-9 5202
20
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
21
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
22
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
23
Somatostatin Approved, Investigational Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
24
Levoleucovorin Approved, Investigational Phase 2, Phase 3,Phase 1 68538-85-2
25
Methylene blue Approved, Investigational Phase 3 61-73-4
26
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
27
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
28
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
29
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
30 lanreotide Approved Phase 3,Phase 2 108736-35-2
31
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
32
leucovorin Approved, Nutraceutical Phase 2, Phase 3,Phase 3,Phase 1 58-05-9 143 6006
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
34 tannic acid Approved, Nutraceutical Phase 3
35 Pancreatic Polypeptide Investigational Phase 2, Phase 3,Phase 1,Not Applicable 59763-91-6
36 Hormone Antagonists Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
38 Hormones Phase 3,Phase 2,Phase 1
39 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
40 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
41 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1
43 Antimetabolites Phase 2, Phase 3,Phase 1
44 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
45 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
46 Angiopeptin Phase 3,Phase 2
47 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
48 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
49 Pharmaceutical Solutions Phase 3,Phase 2
50 Antifungal Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 71)
# Name Status NCT ID Phase Drugs
1 Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients Completed NCT00564564 Phase 4 Quetiapine;Clomipramine
2 Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment Completed NCT00466609 Phase 4 Clomipramine (fluoxetine plus clomipramine);Quetiapine (fluoxetine plus quetiapine);Placebo (fluoxetine plus placebo)
3 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
4 An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Completed NCT00774930 Phase 3 Lanreotide;Placebo
5 Telotristat Etiprate for Carcinoid Syndrome Therapy Completed NCT02063659 Phase 3 Telotristat etiprate;Placebo
6 TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Completed NCT01677910 Phase 3 Telotristat etiprate;Placebo-matching telotristat etiprate
7 Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Completed NCT00412061 Phase 3 Octreotide;Placebo;Everolimus
8 Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) Completed NCT01626378 Phase 3 TRx0237;Placebo
9 Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Active, not recruiting NCT02026063 Phase 3 Telotristat etiprate tablets (250 mg)
10 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
11 Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome Terminated NCT00092287 Phase 3 lanreotide Autogel (somatostatin analogue);Sandostatin long acting release (LAR) Depot (somatostatin analogue)
12 Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer Unknown status NCT00019474 Phase 2 fluorouracil;hydroxyurea
13 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Completed NCT01104415 Phase 2 Low Dose LX1606 - Day 1 (start);Mid-low dose LX1606 - Day 15 (start);Mid-high dose LX1606 - Day 29 (start);High dose LX1606 - Day 43 (start)
14 Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Completed NCT00853047 Phase 2 Low Dose LX1606 Part 1;Mid-Low Dose LX1606 Part 1;Mid-High Dose LX1606 Part 1;High Dose LX1606 Part 1;Part 2 LX1606 Expanded Cohort;Placebo;LX1606 Open Label Dose Extension;LX1606 Open Label Extension 2;LX1606 Open Label Extension 3
15 Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors Completed NCT00088595 Phase 2 Pasireotide (SOM230)
16 Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Completed NCT02299089 Phase 2 octreotide FluidCrystal® injection depot
17 Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors Completed NCT00002470 Phase 2 fluorouracil
18 Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors Completed NCT00055809 Phase 2
19 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
21 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
22 Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma Completed NCT00093782 Phase 2 temsirolimus
23 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
24 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
25 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
26 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
27 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
28 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
29 Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction Completed NCT00004911 Phase 1, Phase 2
30 Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction Completed NCT00004910 Phase 1, Phase 2
31 Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer Completed NCT00005049 Phase 2 carboplatin;cisplatin;floxuridine
32 Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors Recruiting NCT01782443 Phase 2 Ziv-aflibercept
33 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
34 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors Active, not recruiting NCT01731925 Phase 2 Lanreotide;Placebo (for sunitinib);Sunitinib
35 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
36 AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm Not yet recruiting NCT03453489 Phase 2 Telotristat Etiprate
37 Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Terminated NCT00884715 Phase 1, Phase 2 Octreotide
38 Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Terminated NCT01018953 Phase 2 BIM 23A760
39 P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome Terminated NCT01886287 Phase 2 Octreotide LAR
40 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
41 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Terminated NCT00903396 Phase 2 palonosetron hydrochloride
42 Study of Panitumumab in the Treatment of Carcinoid Syndrome Withdrawn NCT01172717 Phase 2 Panitumumab
43 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
44 An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males Completed NCT01932528 Phase 1 500 mg [14C]-LX1606
45 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
46 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
47 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
48 Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Completed NCT01155258 Phase 1 temsirolimus;vinorelbine ditartrate
49 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Completed NCT00655655 Phase 1 everolimus;vatalanib
50 Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT00654160 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium

Search NIH Clinical Center for Serotonin Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Serotonin Syndrome

Anatomical Context for Serotonin Syndrome

MalaCards organs/tissues related to Serotonin Syndrome:

41
Liver, Bone, Lung, Breast, Heart, Testes, Endothelial

Publications for Serotonin Syndrome

Articles related to Serotonin Syndrome:

(show top 50) (show all 623)
# Title Authors Year
1
Association of Coprescription of Triptan Antimigraine Drugs and Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor Antidepressants With Serotonin Syndrome. ( 29482205 )
2018
2
Serotonin Syndrome in Obstetrics: A Case Report and Review of Management. ( 29901770 )
2018
3
Serotonin, Syndrome ( 29493999 )
2018
4
Serotonin syndrome during a heat wave. ( 29437313 )
2018
5
Delayed Serotonin Syndrome in the Setting of a Mixed Fluoxetine and Serotonin Antagonist Overdose. ( 29795058 )
2018
6
Opioid-induced inhibition of the human 5-HT and noradrenaline transporters in vitro: link to clinical reports of serotonin syndrome. ( 29210063 )
2018
7
Fentanyl-Associated Serotonin Syndrome and Chest Wall Rigidity in an Intensive Care Unit Patient. ( 29965805 )
2018
8
Severe Serotonin Syndrome in an Autistic New Psychoactive Substance User After Consumption of Pills Containing Methoxphenidine and I+-Methyltryptamine. ( 29210865 )
2018
9
Serotonin Syndrome Presenting with Concomitant Tramadol and Diphenhydramine Use: A Case Report of an Unlikely Side-Effect. ( 29872601 )
2018
10
Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures. ( 29752906 )
2018
11
Serotonin syndrome versus neuroleptic malignant syndrome: a case report. ( 29616715 )
2018
12
A Mixed Presentation of Serotonin Syndrome vs Neuroleptic Malignant Syndrome in a 12-Year-Old Boy. ( 29698346 )
2018
13
Implications of Off-Target Serotoninergic Drug Activity - An Analysis of Serotonin Syndrome Reports using a Systematic Bioinformatics Approach. ( 29972695 )
2018
14
Serotonin Syndrome Following Septal Myectomy in Association With Fentanyl and Methylene Blue: A Case Report. ( 29571985 )
2018
15
Conservative management of severe serotonin syndrome with coma, myoclonus, and crossed-extensor reflex complicated by hepatic encephalopathy. ( 29686575 )
2018
16
Diaphoresis: A Presentation of Serotonin Syndrome From Vortioxetine. ( 29917334 )
2018
17
Association Between Serotonin Syndrome and Second-Generation Antipsychotics via Pharmacological Target-Adverse Event Analysis. ( 29575568 )
2018
18
The role of chronic nutritional supplements consumption in a fulminant serotonin syndrome due to citalopram intoxication. ( 29317102 )
2018
19
Serotonergic medications, herbal supplements, and perioperative serotonin syndrome. ( 28667541 )
2017
20
Metoclopramide-induced Serotonin Syndrome. ( 28321081 )
2017
21
Vasoplegic Shock Treated with Methylene Blue Complicated by Severe Serotonin Syndrome. ( 29134498 )
2017
22
Malignant Syndrome and Serotonin Syndrome in a General Hospital Setting: Clinical Features, Frequency and Prognosis. ( 28943544 )
2017
23
Cervical Spinal Cord Stimulation with Concomitant Serotonin Norepinephrine Reuptake Inhibitor Therapy Leading to the Serotonin Syndrome. ( 28057811 )
2017
24
Controversies in Serotonin Syndrome Diagnosis and Management: A Review. ( 29207768 )
2017
25
Methylene blue-induced serotonin syndrome after left ventricular assist device implantation: A case report and literature review. ( 28655448 )
2017
26
A review of vilazodone exposures with focus on serotonin syndrome effects. ( 28594246 )
2017
27
Comment on Tapentadol and Serotonin Syndrome. ( 28515499 )
2017
28
Comment on "Probable Tapentadol-Associated Serotonin Syndrome After Overdose". ( 28515500 )
2017
29
Staying Topical: An Unusual Case of Serotonin Syndrome. ( 28806389 )
2017
30
Serotonin syndrome caused by drug to drug interaction between escitalopram and dextromethorphan. ( 28784915 )
2017
31
Serotonin Syndrome from 5-Hydroxytryptophan Supplement Ingestion in a 9-Month-Old Labrador Retriever. ( 28210931 )
2017
32
Codeine Precipitating Serotonin Syndrome in a Patient in Therapy with Antidepressant and Triptan. ( 28783942 )
2017
33
Serotonin Syndrome in Tapentadol Literature: Systematic Review of Original Research. ( 29336654 )
2017
34
Fatal serotonin syndrome in a patient with Marchiafava-Bignami disease: Combined neurological and psychiatric emergency. ( 29169770 )
2017
35
Famotidine-induced reversal of meperidine-related serotonin syndrome: a case report. ( 28367296 )
2017
36
To the Editor: Serotonin syndrome. ( 28530902 )
2017
37
Serotonin syndrome in patients with headache disorders. ( 28784913 )
2017
38
Epidemiology and Economic Burden of Serotonin Syndrome With Concomitant Use of Serotonergic Agents: A Retrospective Study Utilizing Two Large US Claims Databases. ( 29286588 )
2017
39
Rare case of severe serotonin syndrome leading to bilateral compartment syndrome. ( 28258180 )
2017
40
Incidence of Serotonin Syndrome With Combined Use of Linezolid and Serotonin Reuptake Inhibitors Compared With Linezolid Monotherapy. ( 28796019 )
2017
41
Serotonin Syndrome Following Combined Administration of Dopaminergic and Noradrenergic Agents in a Patient With Akinetic Mutism After Frontal Intracerebral Hemorrhage: A Case Report. ( 28622210 )
2017
42
Dietary Supplement-Drug Interaction-Induced Serotonin Syndrome Progressing to Acute Compartment Syndrome. ( 28839121 )
2017
43
Serotonin Syndrome in a Pediatric Patient After Vilazodone Ingestion. ( 28350718 )
2017
44
Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. ( 28975823 )
2017
45
Serotonin syndrome due to co-administration of linezolid and methadone. ( 28956544 )
2017
46
In Reply: Serotonin syndrome. ( 28530903 )
2017
47
Probable Tapentadol-Associated Serotonin Syndrome After Overdose. ( 27303080 )
2016
48
Methylene Blue Causing Serotonin Syndrome Following Cystocele Repair. ( 27617215 )
2016
49
Reply to Wolvetang et al: "Serotonin Syndrome After Methylene Blue Administration During Cardiac Surgery: A Case Report and Review". ( 27554232 )
2016
50
New Insights on Different Response of MDMA-Elicited Serotonin Syndrome to Systemic and Intracranial Administrations in the Rat Brain. ( 27192423 )
2016

Variations for Serotonin Syndrome

Expression for Serotonin Syndrome

Search GEO for disease gene expression data for Serotonin Syndrome.

Pathways for Serotonin Syndrome

Pathways related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.19 GHRH HTR1A HTR2A OXT PYY SST
2 11.55 CYP2D6 HTR1A HTR2A HTR3A MAOA MAOB
3 11.44 HTR1A HTR2A HTR3A MAOA SLC6A4 SST
4
Show member pathways
11.33 CYP2D6 CYP3A4 SLC6A4
5 11 HTR1A HTR2A HTR3A MAOA SLC6A4
6
Show member pathways
10.61 MAOA MAOB
7 10.55 MAOA MAOB
8
Show member pathways
10.48 MAOA MAOB

GO Terms for Serotonin Syndrome

Cellular components related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CGB3 CHGA GAST GHRH IFNA2 NOTCH1
2 extracellular space GO:0005615 9.28 CGB3 CHGA GAST GHRH IFNA2 OXT

Biological processes related to Serotonin Syndrome according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 HTR2A MAOB SLC6A4 SST
2 neuropeptide signaling pathway GO:0007218 9.8 PYY SSTR1 TAC1
3 memory GO:0007613 9.74 HTR2A OXT SLC6A4
4 chemical synaptic transmission GO:0007268 9.72 HTR1A HTR2A HTR3A SST TAC1
5 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.71 HTR1A HTR2A SSTR1
6 vasoconstriction GO:0042310 9.63 HTR1A SLC6A4
7 cell-cell signaling GO:0007267 9.63 CGB3 GHRH IFNA2 PYY SST TAC1
8 negative regulation of cell-substrate adhesion GO:0010812 9.62 MEN1 NOTCH1
9 positive regulation of ossification GO:0045778 9.61 OXT TAC1
10 positive regulation of renal sodium excretion GO:0035815 9.61 OXT TAC1
11 oxidative demethylation GO:0070989 9.6 CYP2D6 CYP3A4
12 sleep GO:0030431 9.59 HTR2A OXT
13 regulation of behavior GO:0050795 9.58 HTR1A HTR2A
14 neurotransmitter catabolic process GO:0042135 9.58 MAOA MAOB
15 response to steroid hormone GO:0048545 9.58 MAOB OXT SST
16 behavior GO:0007610 9.56 HTR1A HTR2A
17 dopamine catabolic process GO:0042420 9.55 MAOA MAOB
18 heterocycle metabolic process GO:0046483 9.52 CYP2D6 CYP3A4
19 drug catabolic process GO:0042737 9.51 CYP2D6 CYP3A4
20 regulation of signaling receptor activity GO:0010469 9.5 CGB3 GAST GHRH IFNA2 OXT PYY
21 monoterpenoid metabolic process GO:0016098 9.49 CYP2D6 CYP3A4
22 regulation of hormone secretion GO:0046883 9.48 HTR1A HTR2A
23 sperm ejaculation GO:0042713 9.46 OXT SLC6A4
24 serotonin receptor signaling pathway GO:0007210 9.43 HTR1A HTR2A
25 response to food GO:0032094 9.43 GAST GHRH OXT
26 alkaloid catabolic process GO:0009822 9.37 CYP2D6 CYP3A4
27 G-protein coupled receptor signaling pathway GO:0007186 9.32 CGB3 GAST GHRH HTR1A HTR2A OXT

Molecular functions related to Serotonin Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 primary amine oxidase activity GO:0008131 9.16 MAOA MAOB
2 serotonin binding GO:0051378 9.13 HTR1A HTR2A HTR3A
3 hormone activity GO:0005179 9.02 CGB3 GAST OXT PYY SST

Sources for Serotonin Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....